查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995464

癌症免疫疗法药物市场：2026-2032年全球市场预测（依治疗方法、给药途径、癌症类型、作用机制、最终用户和分销管道划分）

Cancer Immunotherapy Drugs Market by Therapy Type, Route Of Administration, Cancer Type, Mechanism Of Action, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症免疫疗法药物市场价值将达到 2,718.8 亿美元，到 2026 年将成长至 2,946.3 亿美元，到 2032 年将达到 4,852.2 亿美元，复合年增长率为 8.62%。

主要市场统计数据
基准年 2025 2718.8亿美元
预计年份：2026年 2946.3亿美元
预测年份 2032 4852.2亿美元
复合年增长率 (%) 8.62%

免疫肿瘤学的突破如何改变癌症治疗和药物研发的临床实践和商业策略。

癌症免疫疗法领域正处于一个关键的转折点，生物学、临床实践和商业策略在此交汇，重新定义癌症的治疗和管理方式。免疫肿瘤学的进步已将治疗范式从特异性细胞毒性疗法转变为精准利用和调节免疫系统的治疗方法。随着科学知识的不断深入，新的机制正从实验室走向临床实践，而现有的药物组合也正在透过改进製剂、联合治疗和优化患者选择而持续发展。在这种动态变化的环境中，相关人员需要整合复杂的数据集，包括作用机制、癌症类型、治疗方案、给药途径和临床环境等信息，才能做出明智的决策。

这是一个重大的科学、营运和商业性转折点，从根本上改变了肿瘤医学整体免疫疗法的开发、交付和实施。

近年来，免疫疗法领域经历了变革性的变化，这主要得益于科学突破以及新药研发和应用方面的实践转变。细胞疗法和基因改造肿瘤病毒等新型治疗方法正在重新定义持续疗效的潜力，而查核点抑制剂和细胞激素生物学的迭代改进则不断扩大治疗范围。同时，疫苗、细胞疗法产品和查核点调变器的合理联合治疗策略正在加速发展，使人们对给药顺序和协同效应有了更深入的了解。为了因应这些发展，申办公司正在重新审视其临床试验设计、生物标记策略和监管合作，以支持加速核准流程。

2025 年关税趋势将如何改变肿瘤生技药品的复杂供应链、生产在地化决策和市场进入策略？

2025年的关税和贸易政策变化将进一步增加支撑生物製药和先进疗法的全球供应链的复杂性。某些进口商品关税的提高可能会推高用于细胞疗法、溶瘤平台和製剂细胞激素生产的原材料、一次性组件和专用设备的成本。因此，研发专案可能面临更高的采购成本和更长的关键前置作业时间交付週期，这可能会影响生产计划和库存策略。为了因应这种情况，各公司正在寻求供应商多元化、探索本土化生产方案，并重新评估策略库存缓衝，以确保临床供应和商业化的连续性。

准确且多方面的细分洞察，将作用机制、癌症类型、治疗线、给药途径和分销特征与策略重点相结合。

明确界定有效的细分市场有助于在研发和商业化的每个阶段进行策略优先排序。在基于作用机制分析治疗方法时，必须区分癌症疫苗、CAR-T细胞疗法、CTLA-4抑制剂、细胞激素、溶瘤病毒、PD-1抑制剂和PD-L1抑制剂，因为每一类疗法在生产、证据生成和患者选择方面都有不同的要求。以癌症类型进行治疗又增加了另一层复杂性。膀胱癌、白血病、淋巴瘤、包括多发性骨髓瘤在内的骨髓恶性肿瘤、肾癌、非小细胞肺癌及其亚型以及恶性黑色素瘤，每种癌症都有其独特的生物学特征、标准治疗基础和疗效评估指标，这些都会影响临床试验设计和医保报销方面的讨论。

一个务实的区域观点，协调美洲、欧洲、中东、非洲和亚太地区的监管多样性、基础设施差异和付款方期望。

区域趋势对发展重点、市场进入策略和商业性实施有显着影响。在美洲，法律规范和支付模式强调疗效和真实世界数据（REW），成熟的专业医疗网络和学术机构有助于受试者参与复杂的临床试验，并促进先进治疗方法的引入。在欧洲、中东和非洲，监管路径和报销机制的多样性要求制定个人化的价值提案和区域差异化的市场进入策略，这促使相关人员应对各种定价谈判和专业疗法的供给能力。同时，亚太市场的基础设施和政策重点则截然不同。多个国家正在大力投资生物製造和监管现代化，这为区域製造伙伴关係以及透过本地临床试验和桥接研究加速市场准入创造了机会。

竞争格局和合作趋势表明，科学差异化和卓越营运的融合是长期成功和市场进入潜力的关键。

免疫肿瘤领域的竞争格局由成熟的生物製药公司、专业生物技术公司以及一体化研发受託製造厂商（IDMO）组成。该领域的领导企业利用强大的临床研发管线、互补的平台技术和策略伙伴关係来拓展适应症并延长疗效持续时间。同时，新兴企业专注于独特的作用机制和细胞平台，打造差异化的价值提案，进而吸引策略性授权和收购。在整个价值链中，能够提供可靠的生产品质、扩充性的供应链解决方案和监管专业知识的服务供应商正成为不可或缺的合作伙伴。

采取针对性的策略行动，加强研发管线，保障供应链，加速研发人员、支付者和医疗服务提供者获得创新肿瘤免疫疗法的途径。

产业领导者应优先采取一系列措施，将策略洞察转化为可衡量的成果。首先，透过整合基于生物标记的患者选择和适应性试验设计来优化临床开发，从而降低后期专案风险并产生令人信服的疗效比较证据。其次，透过供应商多元化、投资区域灌装和包装能力以及确保关键零件的储备库存来消除生产和供应链的脆弱性，从而降低关税相关成本波动和物流中断带来的风险。第三，儘早与保险公司和医疗服务提供者合作，共同製定价值论证计划，该计划应包含真实世界数据 (REW) 的收集，并在适当情况下采用基于结果的合约。

一种稳健的跨部门调查方法，结合临床证据、监管审查、专家访谈和情境分析，为策略决策提供支援。

本分析整合了来自同行评审的临床文献、监管指导文件、公开资料以及对行业专家、临床医生和供应链专家的访谈证据。调查方法采用跨领域三角测量法，将临床数据与营运和商业指标结合，从而整体情况展现竞争格局。关键意见领袖（KOL）的定性见解经过系统验证，并与已记录的试验结果和监管先例检验对，以确保其一致性并确定可操作的实施要点。

结论强调，临床创新需要营运韧性和与支付方意愿相符的证据，以确保可持续的取得和影响。

免疫疗法领域日新月异，蕴藏着巨大的临床潜力，但要充分发挥潜力，创新与实施必须紧密结合。科学进步为多种癌症类型的变革性治疗铺平了道路，但确保患者广泛获得治疗的途径却受到生产复杂性、支付方期望和区域监管差异等因素的影响。因此，成功的关键在于将针对特定机制的证据与切实可行的营运计划相结合，这些计划需考虑给药途径的实际情况、临床经济学以及分销管道的限制。唯有如此，企业才能将治疗差异化转化为永续的临床和商业性效益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的癌症免疫疗法药物市场

  • 查核点抑制剂
  • 单株抗体（查核点除外）
    • 裸单株抗体
    • 抗体药物复合体
    • 双特异性抗体
  • 细胞疗法
    • CAR-T细胞疗法
    • TCR-T细胞疗法
    • 肿瘤浸润淋巴细胞疗法
  • 癌症疫苗
    • 用于治疗的癌症疫苗
    • 预防性癌症疫苗
  • 细胞激素疗法
    • 白细胞介素疗法
    • 干扰素疗法
  • 溶瘤病毒疗法

第九章：癌症免疫疗法药物市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十章：以癌症类型分類的癌症免疫疗法药物市场

  • 固态肿瘤
    • 肺癌
      • 非小细胞肺癌
      • 小细胞肺癌
    • 恶性黑色素瘤
    • 乳癌
    • 泌尿生殖系统癌症
      • 肾臟细胞癌
      • 膀胱癌
      • 摄护腺癌
    • 胃肠道癌症
      • 结肠癌
      • 胃癌
      • 肝细胞癌
      • 胰臟癌
    • 头颈癌
    • 妇科癌症
  • 骨髓恶性肿瘤
    • 白血病
      • 急性淋巴性白血病
      • 急性骨髓性白血病
      • 慢性淋巴性白血病
      • 慢性骨髓性白血病
    • 淋巴瘤
      • 何杰金氏淋巴瘤
      • 非何杰金氏淋巴瘤
    • 多发性骨髓瘤

第十一章：以作用机制分類的癌症免疫疗法药物市场

  • 免疫查核点抑制
  • 免疫细胞衔接器
    • 双特异性T细胞衔接器
    • 双特异性NK细胞衔接器
  • 免疫系统调变器
    • T细胞活化剂
    • NK细胞活化剂
    • 树突状细胞活化剂
  • 肿瘤微环境调变器
    • 血管新生调节因子
    • 髓系细胞调变器
    • 间质修饰剂
  • 肿瘤溶解性和可溶性药物
  • 癌症抗原标靶化

第十二章 癌症免疫疗法药物市场：依最终用户划分

  • 门诊部
  • 医院
  • 专科诊所

第十三章：癌症免疫疗法药物市场：按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 癌症免疫疗法药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 癌症免疫疗法药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 癌症免疫疗法药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国癌症免疫疗法药物市场

第十八章：中国癌症免疫治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • CARsgen Therapeutics
  • Celldex Therapeutics, Inc.
  • ElevateBio
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Ikena Oncology
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OSE Immunotherapeutics SA
  • Pfizer Inc.
  • QIAGEN NV
  • Sanofi SA
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4103B31E0955

The Cancer Immunotherapy Drugs Market was valued at USD 271.88 billion in 2025 and is projected to grow to USD 294.63 billion in 2026, with a CAGR of 8.62%, reaching USD 485.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 271.88 billion
Estimated Year [2026] USD 294.63 billion
Forecast Year [2032] USD 485.22 billion
CAGR (%) 8.62%

How breakthroughs in immune-oncology are reshaping clinical practice and commercial strategy across oncology care delivery and drug development

The field of cancer immunotherapy stands at a pivotal inflection point where biology, clinical practice, and commercial strategy converge to redefine how oncology is treated and managed. Advances in immune-oncology have shifted paradigms from non-specific cytotoxic approaches to therapies that harness and modulate the immune system with precision. As scientific understanding deepens, novel mechanisms are moving from bench to bedside, and established classes continue to evolve through improved formulations, combination regimens, and refined patient selection. This dynamic landscape requires stakeholders to synthesize complex datasets across mechanism, cancer type, treatment line, delivery route, and care setting in order to make robust decisions.

Clinicians, developers, and commercial leaders must balance therapeutic promise with operational realities such as manufacturing complexity, supply chain security, regulatory expectations, and payer evidence requirements. In this context, strategic foresight and cross-functional integration become essential. By integrating clinical trends with distribution and end-user behavior, organizations can identify where therapeutic differentiation and access pathways create the greatest value. Consequently, this introduction frames the remainder of the executive summary by outlining the forces reshaping immuno-oncology and by emphasizing the need for evidence-driven, pragmatically staged strategies to capture clinical and commercial opportunity.

Key scientific, operational, and commercial inflection points that are fundamentally transforming immunotherapy development, delivery, and adoption across oncology care

Recent years have seen transformative shifts in the immunotherapy landscape driven by scientific breakthroughs and pragmatic changes in how new agents are developed and deployed. Emerging modalities such as cell-based therapies and engineered oncolytic viruses are redefining the possibilities for durable responses, while iterative enhancements in checkpoint inhibition and cytokine biology continue to expand therapeutic windows. At the same time, combination strategies that rationally pair vaccines, cellular products, and checkpoint modulators are accelerating, generating a more nuanced understanding of sequencing and synergy. These developments are prompting sponsors to reconsider clinical trial design, biomarker strategies, and regulatory engagement to support accelerated pathways.

Operational shifts are equally consequential: decentralized clinical trials, advances in manufacturing automation, and more robust cold-chain logistics have reduced barriers for complex biologics. Simultaneously, payers and health systems are placing greater emphasis on real-world outcomes and cost-effectiveness, which is influencing pricing discussions and the adoption of value-based contracting. The interplay between novel science and these delivery models signals a maturation of the field: innovation is increasingly measured not only by clinical efficacy but also by scalability, patient access, and sustained health-economic value. Stakeholders who align scientific differentiation with pragmatic commercialization plans will be best positioned to capture long-term clinical and market relevance.

How 2025 tariff dynamics are reshaping supply chains, manufacturing localization decisions, and commercial access strategies for complex oncology biologics

Policy shifts concerning tariffs and trade in 2025 have introduced additional complexity to the global supply chains that support biologics and advanced therapies. Increased duties on certain imported goods can raise the cost base for raw materials, single-use components, and specialized equipment used in the manufacture of cell therapies, oncolytic platforms, and formulated cytokines. As a result, development programs may face higher procurement costs and longer lead times for critical inputs, which in turn can influence manufacturing scheduling and inventory strategies. Companies are responding by reassessing supplier diversification, onshoring options, and strategic inventory buffers to maintain continuity of clinical supply and commercial launches.

Moreover, tariffs affect distribution economics and may alter the comparative attractiveness of regional manufacturing hubs. In response, organizations are accelerating initiatives to localize production for priority markets and to establish regional fill-finish capabilities that mitigate cross-border cost volatility. These decisions carry regulatory and quality implications that require early engagement with authorities and payers to ensure alignment on product comparability and substitution practices. Over time, tariff-driven adjustments are likely to influence partnership structures, contract terms with CMOs, and capital allocation for manufacturing capacity. Stakeholders should therefore incorporate tariff scenarios into their supply chain risk assessments and commercial planning to preserve access and manage margin pressure without compromising clinical timelines.

Precise multi-dimensional segmentation insights that align mechanism, cancer type, treatment line, administration route, and distribution characteristics to strategic priorities

Effective segmentation clarity drives strategic prioritization across development and commercialization pathways. When analyzing therapies by mechanism of action, it is essential to differentiate between cancer vaccines, CAR T cell therapies, CTLA-4 inhibitors, cytokines, oncolytic viruses, PD-1 inhibitors, and PD-L1 inhibitors because each category carries distinct manufacturing, evidence-generation, and patient-selection requirements. Treatment across different cancer types introduces another layer of nuance: bladder cancer, hematologic malignancies including leukemia, lymphoma, and multiple myeloma, kidney cancer, lung cancer with its non-small cell and small cell subtypes, and melanoma each present unique biology, standard-of-care backbones, and outcome measures that influence trial design and reimbursement conversations.

Treatment line segmentation-first line, second line, and third line and beyond-affects both clinical endpoints and market access strategies, as earlier-line approvals often require broader safety and comparative effectiveness data. Route of administration considerations across intravenous, oral, and subcutaneous formats inform patient adherence, site-of-care economics, and cold-chain logistics, which in turn shape commercial positioning. Finally, end-user and distribution channel segmentation, spanning ambulatory care centers, hospitals, and specialty clinics and flowing through hospital pharmacies, online pharmacies, and retail pharmacies, determines real-world uptake patterns and the operational investments needed to support prescribing, dispensing, and patient support programs. Integrating these dimensions enables differentiated go-to-market plans and targeted evidence generation to address clinical and payer expectations.

Actionable regional perspectives that reconcile regulatory diversity, infrastructure differences, and payer expectations across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on development priorities, access strategies, and commercial execution. In the Americas, regulatory frameworks and payer models emphasize outcomes and real-world evidence, with established specialty care networks and academic centers that facilitate complex trial enrollment and adoption of advanced therapies. Across Europe, Middle East & Africa, the heterogeneity of regulatory pathways and reimbursement systems requires tailored value dossiers and differentiated regional market access strategies, and stakeholders must navigate diverse pricing negotiations as well as capacity constraints for specialized therapies. Meanwhile, Asia-Pacific markets vary widely in infrastructure and policy priorities; several countries are investing heavily in biomanufacturing and regulatory modernization, which creates opportunities for regional manufacturing partnerships and accelerated market entry through local trials or bridging studies.

Consequently, companies should adopt a regionally calibrated approach that balances centralized development assets with decentralized commercialization tactics. This means leveraging local clinical centers of excellence to generate region-specific evidence, aligning manufacturing footprint decisions with tariff and logistics realities, and customizing patient support programs to match healthcare delivery models. Cross-border collaboration and early payer engagement are essential levers to harmonize value communication and to secure timely access across these diverse regions, while maintaining compliance with evolving local regulatory expectations.

Competitive and partnership landscapes revealing how scientific differentiation combined with operational excellence determines long-term success and access potential

Competitive dynamics in immuno-oncology are being shaped by a mix of established biopharmaceutical firms, specialized biotechnology companies, and integrated contract development and manufacturing organizations. Leaders in the space are leveraging robust clinical pipelines, complementary platform technologies, and strategic partnerships to expand indications and to enhance the durability of response. Meanwhile, emerging companies are focusing on niche mechanisms or cell-based platforms to create differentiated value propositions that can attract strategic licensing or acquisition interest. Across the value chain, service providers that can demonstrate reliable manufacturing quality, scalable supply-chain solutions, and regulatory expertise are becoming indispensable allies.

Strategic collaborations between developers, payers, and provider networks are increasingly common as stakeholders seek to align clinical outcomes with reimbursement models. Intellectual property portfolios remain central to competitive defensibility, but operational excellence in manufacturing and distribution is an equally critical differentiator in delivering timely access. Consequently, organizations that combine strong scientific rationale with pragmatic execution capabilities-especially in complex modalities like CAR T cell therapies and oncolytic viruses-tend to outperform peers in both clinical impact and market traction. Investors and corporate strategists should therefore evaluate both pipeline science and the operational infrastructure underpinning commercialization readiness.

Targeted strategic actions for developers, payers, and providers to strengthen pipelines, secure supply chains, and accelerate access to innovative oncology immunotherapies

Industry leaders should pursue a set of prioritized actions that translate strategic insight into measurable results. First, optimize clinical development by integrating biomarker-driven patient selection and adaptive trial designs to de-risk late-stage programs and to generate compelling comparative effectiveness evidence. Second, deconstruct manufacturing and supply-chain vulnerabilities by diversifying suppliers, investing in regional fill-finish capacity, and establishing contingency inventories for critical components, thereby reducing exposure to tariff-induced cost volatility and logistical disruption. Third, engage payers and providers early to co-develop value demonstration plans that incorporate real-world evidence collection and outcomes-based contracting where appropriate.

In parallel, companies should refine commercial models to reflect route-of-administration and site-of-care economics, ensuring that patient support and specialty distribution capabilities are aligned with the needs of intravenous, subcutaneous, and oral therapies. Additionally, pursue targeted partnerships and licensing agreements to accelerate access in regions with manufacturing or regulatory constraints, and prioritize investments in digital health tools that improve patient monitoring and adherence. Finally, maintain a disciplined portfolio approach that balances high-risk, high-reward novel modalities with incremental innovations that enhance safety, convenience, and cost-effectiveness. These coordinated actions will improve the probability of clinical and commercial success while preserving strategic optionality.

A robust cross-functional methodology combining clinical evidence, regulatory review, expert interviews, and scenario analysis to inform strategic decision-making

This analysis synthesizes evidence from peer-reviewed clinical literature, regulatory guidance documents, public filings, and primary interviews with industry experts, clinicians, and supply-chain specialists. The methodology employed a cross-functional triangulation approach that aligns clinical data with operational and commercial indicators to produce a holistic view of the competitive landscape. Qualitative insights from key opinion leaders were systematically validated against documented trial outcomes and regulatory precedents to ensure consistency and to surface practical considerations for implementation.

Where possible, regulatory timelines and policy developments were reviewed to assess implications for access and commercialization planning. Supply-chain and manufacturing evaluations incorporated publicly available information on capacity, technology platforms, and recent investments, supplemented by expert interviews to capture near-term operational risks. Finally, scenario analysis was used to explore the implications of tariff changes, regional production decisions, and payer adoption patterns. This methodology provides a robust foundation for strategic decision-making by integrating multidimensional evidence while acknowledging residual uncertainties that warrant ongoing monitoring during program execution.

Concluding synthesis emphasizing that clinical innovation must be matched with operational resilience and payer-aligned evidence to achieve enduring access and impact

The evolving immunotherapy landscape offers meaningful clinical potential, but realizing that potential requires disciplined alignment between innovation and execution. Scientific advances open pathways for transformative responses in multiple cancer types, yet the path to broad patient access is shaped by manufacturing complexity, payer expectations, and regional regulatory heterogeneity. Success will therefore hinge on integrating mechanism-specific evidence with pragmatic operational plans that account for route-of-administration realities, site-of-care economics, and distribution-channel constraints. By doing so, organizations can convert therapeutic differentiation into sustainable clinical and commercial impact.

Forward-looking stakeholders should prioritize adaptive development strategies, robust supply-chain planning, and early payer engagement to reduce execution risk. In addition, regional strategies that leverage local capabilities and align with policy environments will facilitate faster access and improved patient outcomes. Ultimately, the combination of rigorous science, operational resilience, and value-focused evidence will determine which therapies achieve durable clinical adoption and enduring market relevance across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Drugs Market, by Therapy Type

  • 8.1. Checkpoint Inhibitors
  • 8.2. Monoclonal Antibodies (Non-Checkpoint)
    • 8.2.1. Naked Monoclonal Antibodies
    • 8.2.2. Antibody Drug Conjugates
    • 8.2.3. Bispecific Antibodies
  • 8.3. Adoptive Cell Therapies
    • 8.3.1. CAR-T Cell Therapies
    • 8.3.2. TCR-T Cell Therapies
    • 8.3.3. Tumor-Infiltrating Lymphocyte Therapies
  • 8.4. Cancer Vaccines
    • 8.4.1. Therapeutic Cancer Vaccines
    • 8.4.2. Prophylactic Cancer Vaccines
  • 8.5. Cytokine Therapies
    • 8.5.1. Interleukin-Based Therapies
    • 8.5.2. Interferon-Based Therapies
  • 8.6. Oncolytic Virus Therapies

9. Cancer Immunotherapy Drugs Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Cancer Immunotherapy Drugs Market, by Cancer Type

  • 10.1. Solid Tumors
    • 10.1.1. Lung Cancer
      • 10.1.1.1. Non-Small Cell Lung Cancer
      • 10.1.1.2. Small Cell Lung Cancer
    • 10.1.2. Melanoma
    • 10.1.3. Breast Cancer
    • 10.1.4. Genitourinary Cancers
      • 10.1.4.1. Renal Cell Carcinoma
      • 10.1.4.2. Bladder Cancer
      • 10.1.4.3. Prostate Cancer
    • 10.1.5. Gastrointestinal Cancers
      • 10.1.5.1. Colorectal Cancer
      • 10.1.5.2. Gastric Cancer
      • 10.1.5.3. Hepatocellular Carcinoma
      • 10.1.5.4. Pancreatic Cancer
    • 10.1.6. Head And Neck Cancers
    • 10.1.7. Gynecological Cancers
  • 10.2. Hematologic Malignancies
    • 10.2.1. Leukemias
      • 10.2.1.1. Acute Lymphoblastic Leukemia
      • 10.2.1.2. Acute Myeloid Leukemia
      • 10.2.1.3. Chronic Lymphocytic Leukemia
      • 10.2.1.4. Chronic Myeloid Leukemia
    • 10.2.2. Lymphomas
      • 10.2.2.1. Hodgkin Lymphoma
      • 10.2.2.2. Non-Hodgkin Lymphoma
    • 10.2.3. Multiple Myeloma

11. Cancer Immunotherapy Drugs Market, by Mechanism Of Action

  • 11.1. Immune Checkpoint Blockade
  • 11.2. Immune Cell Engagers
    • 11.2.1. Bispecific T Cell Engagers
    • 11.2.2. Bispecific NK Cell Engagers
  • 11.3. Immune System Modulators
    • 11.3.1. T Cell Activators
    • 11.3.2. NK Cell Activators
    • 11.3.3. Dendritic Cell Activators
  • 11.4. Tumor Microenvironment Modulators
    • 11.4.1. Angiogenesis Modulators
    • 11.4.2. Myeloid Cell Modulators
    • 11.4.3. Stromal Modulators
  • 11.5. Oncolytic And Lytic Agents
  • 11.6. Cancer Antigen Targeting

12. Cancer Immunotherapy Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Cancer Immunotherapy Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Cancer Immunotherapy Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Immunotherapy Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Immunotherapy Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Immunotherapy Drugs Market

18. China Cancer Immunotherapy Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie, Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol Myers Squibb Company
  • 19.12. CARsgen Therapeutics
  • 19.13. Celldex Therapeutics, Inc.
  • 19.14. ElevateBio
  • 19.15. ELI Lilly and Company
  • 19.16. F. Hoffmann-La Roche Ltd
  • 19.17. Gilead Sciences, Inc.
  • 19.18. GlaxoSmithKline PLC
  • 19.19. Ikena Oncology
  • 19.20. Incyte Corporation
  • 19.21. Johnson & Johnson Services, Inc.
  • 19.22. Merck & Co., Inc.
  • 19.23. Novartis AG
  • 19.24. OSE Immunotherapeutics SA
  • 19.25. Pfizer Inc.
  • 19.26. QIAGEN N.V.
  • 19.27. Sanofi SA
  • 19.28. Seattle Genetics Inc.
  • 19.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROPHYLACTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKIN-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERON-BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTRIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD AND NECK CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GYNECOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BISPECIFIC NK CELL ENGAGERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY T CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL ACTIVATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ANGIOGENESIS MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MYELOID CELL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STROMAL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC AND LYTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER ANTIGEN TARGETING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (NON-CHECKPOINT), 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GENITOURINARY CANCERS, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIAS, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMAS, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE CELL ENGAGERS, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNE SYSTEM MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TUMOR MICROENVIRONMENT MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRIC